Last reviewed · How we verify
NCT03704714
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Phase 1, PHASE2 trial testing Cyclophosphamide in Aggressive Non-Hodgkin Lymphoma in 30 participants. Suspended.
11 December 2024
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 November 2018 |
| Primary completion | 11 December 2024 |
| Estimated completion | 11 June 2025 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Cyclophosphamide (cyclophosphamide) — full drug profile →
- Doxorubicin Hydrochloride — full drug profile →
- Nivolumab (nivolumab) — full drug profile →
- Prednisone (prednisone) — full drug profile →
- Quality-of-Life Assessment
- Rituximab
- Vincristine Sulfate (Vincristine Sulfate) — full drug profile →
Conditions studied
- Aggressive Non-Hodgkin Lymphoma — all drugs for Aggressive Non-Hodgkin Lymphoma →
- B-Cell Non-Hodgkin Lymphoma — all drugs for B-Cell Non-Hodgkin Lymphoma →
- CD20 Positive — all drugs for CD20 Positive →
- Diffuse Large B-Cell Lymphoma Unclassifiable — all drugs for Diffuse Large B-Cell Lymphoma Unclassifiable →
Sponsor
Northwestern University
Who can join
18 and older, any sex, with Aggressive Non-Hodgkin Lymphoma or B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2 -
Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.
Škubník J, Pavlíčková VS, Ruml T, Rimpelová S. · · 2021 · cited 86× · PMID 34571726 · DOI 10.3390/biology10090849 -
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.
Berendsen MR, Stevens WBC, van den Brand M, van Krieken JH, et al · · 2020 · cited 27× · PMID 33260693 · DOI 10.3390/cancers12123553 -
The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.
Tomassetti S, Chen R, Dandapani S. · · 2019 · cited 27× · PMID 31040936 · DOI 10.1177/2040620719841591 -
A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M, Bashash D. · · 2023 · cited 15× · PMID 36773442 · DOI 10.1016/j.tranon.2023.101636 -
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, et al · · 2022 · cited 14× · PMID 35767735 · DOI 10.1182/bloodadvances.2022007046 -
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R, Polgarova K, Karolova J, Klener P. · · 2020 · cited 14× · PMID 33260966 · DOI 10.3390/vaccines8040708 -
The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition.
Risbjerg RS, Hansen MV, Sørensen AS, Kragstrup TW. · · 2020 · cited 11× · PMID 32509417 · DOI 10.1186/s40164-020-00167-1
Verify or expand the search:
- PubMed search for NCT03704714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cyclophosphamide
Trials testing the same drug.
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
- NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Aggressive Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT05260957 — CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma · Phase 2 · recruiting
- NCT04231877 — Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive La · Phase 1 · recruiting
- NCT03749018 — Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · Phase 2 · active not recruiting
- NCT01787409 — Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · NA · active not recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03704714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 15 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing